177Lu-3BP-227 for neurotensin receptor 1-targeted therapy of metastatic pancreatic adenocarcinoma – first clinical results

Objective: Neurotensin receptor 1 (NTR1) is overexpressed in ductal pancreatic adenocarcinoma, which is still one of the deadliest cancers with a very poor prognosis. Eligible patients were offered radiopharmaceutical treatment with the novel NTR1 antagonist 177Lu-3BP-227 as salvage therapy. Methods: Six patients with confirmed ductal pancreatic adenocarcinoma who had exhausted all other treatment options received 177Lu-3BP-227 for evaluation of NTR1 expression in vivo. Three patients received treatment activities between 5.1 and 7.5 GBq. Results: Administration of 177Lu-3BP-227 was well tolerated by all patients. Kidneys were identified as the dose-limiting organ. The most severe adverse event was reversible grade 2 anemia. One patient achieved a partial response and experienced significant improvement of symptoms and quality of life. This patient survived 13 months from diagnosis and 11 months from start of 177Lu-3BP-227 therapy. Conclusion: This initial report provides first clinical evidence of the feasibility of treatment of ductal pancreatic adenocarcinoma using 177Lu-3BP-227.

from # & – All via ola Kala on Inoreader http://ift.tt/2z3bYyZ


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s